Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients
Clinical Immunology Communications
; 3:1-5, 2023.
Article
in English
| EMBASE | ID: covidwho-2305064
ABSTRACT
The pandemic caused by the SARS-CoV-2 coronavirus has been especially detrimental to patients with end-stage renal disease. History with other vaccines suggests that patients with renal disease may not respond adequately to the SARS-CoV-2 vaccine. The aim of this study is to evaluate the immunity to SARS-CoV-2 mRNA vaccines in renal patients. Post SARS-CoV-2 vaccination first, and after the booster dose, antibodies and cellular immunity were studied in patients on hemodialysis (N = 20), peritoneal dialysis (N = 10) and renal transplantation (N = 10). After the two doses of vaccine, there was an effective immunity in dialysis patients, with 100% seroconversion and 87% detection of cellular immunity (85% in hemodialysis and 90% in peritoneal dialysis). In contrast, in renal transplant recipients there was only 50% seroconversion and cellular immunity was detected in 30% of patients. After the booster dose, all dialysis patients achieved a cellular and antibody immunity, whereas in transplant patients, despite improvement, 20% did not produce antibodies and in 37.5% cellular immunity could not be detected. The mRNA vaccine plus booster performs excellently in dialysis patients, whereas in kidney transplant recipients, despite the booster, complete immunization is not achieved.Copyright © 2022
End stage kidney disease; Hemodialysis; Peritoneal dialysis; Renal transplant recipient; SARS-CoV-2 vaccine; adult; antibody detection; antibody response; article; cellular immunity; clinical article; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; drug effect; end stage renal disease/su [Surgery]; end stage renal disease/th [Therapy]; female; graft recipient; human; humoral immunity; infection prevention; interferon production; kidney graft; male; seroconversion; vaccination; elasomeran/dt [Drug Therapy]; tozinameran/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Clinical Immunology Communications
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS